|
|
|
| Primary Studies of Monoclonal Antibody Against Fusion Glycoprotein of Human Respiratory Syncytial Virus |
| ZHANG Mei1,2, WANG Xiao-bo1,2, FU Yuan-hui2, FANG Xuan1,2, WANG Xing2, ZHANG Ying2, HE Jin-sheng2 |
1. Department of Immunology, Anhui Medical University, Hefei 230032, China;
2. College of Life Sciences & Bioengineering, Beijing Jiaotong University, Beijing 100044, China |
|
|
|
Abstract Objective: To obtain the hybridoma cell line stably secreting monoclonal antibody (mAb) specific for F glycoprotein (F) of human respiratory syncytial virus (RSV) for the further study of early detection and passive immunotherapy against RSV infection. Methods: The mAbs against F were prepared by hybridoma technology and then the associated characteristics were identified in vitro. Results: The hybridoma cell line of F8 capable of stably secreting mAb was established. It grew well after continuous culture for two months, the resultant supernatant titer of the mAb is 1∶1000. The mAb is IgG1 and its relative affinity (Ka) is 6.8×108 L/mol. The potential epitope recognized by F8 is located around AA 205-222 of F1 subunit of RSV F. Through the immunoenzyme method, the neutralizing activity and fusion inhibition capacity of mAb F8 in vitro were also confirmed. Conclusion: The mAb F8 against RSV F with neutralizing activity was obtained. It lays a foundation for early diagnosis and passive immunotherapy of RSV infection.
|
|
Received: 24 November 2011
Published: 25 February 2012
|
|
|
|
|
|
[1] 陈惠中. 流行性喘憋性肺炎的研究进展. 临床儿科杂志, 2005, 23(9): 602-676. Chen H. The progress on epidemicbronchiolitis. The Journal Of Clinical Pediatrics, 2005, 23(9): 602-676.
[2] 邓洁,钱 渊,朱汝南,等. 2000年冬~2006年春北京地区急性呼吸道感染患儿中呼吸道合胞病毒的监测. 中华儿科杂志, 2006, 44(12): 924-927. Deng J, Qian Y, Zhu R N, et al. Surveillance for respiratory syncytial virus subtypes A and B in children with acute respiratory infections in Beijing during 2000 to 2006 seasons. Chinese Journal of Pediatrics, 2006, 44(12): 924-927.
[3] Wu H, Pfarr D S, Johnson S. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol, 2001,368(3): 652-665.
[4] Chambers P, Prugle C R, Easton A J. Sequence analysis of the gene encoding the fusion glycoprotein of pneumonia virus of mice suggests possible conserved secondary structure elements in paramyxovirus fusion glycoproteins. J Gen Virol, 1992,73(Pt 7):1717-1724.
[5] Beatty J D, Beatty B G, Vlahos W G. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. Journal of Immunological Methods, 1987,100(1-2):173-179.
[6] 王小波,何金生,付远辉,等.呼吸道合胞病毒感染滴度测定方法的建立与比较.中华实验和临床病毒学杂志, 2010,24(2):147-149. Wang X B, He J S, Fu Y H, et al. Research on the methods for titrating respiratory syneytial virus. Chinese J Exp Clin Virol, 2010,24(2):147-149.
[7] Greenough A, Thomas M. Respiratory syncytial virus prevention:past and presents trategies. Expert Opin Pharmacther, 2000,1(6):1195-1201.
[8] Delgado M F. Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nature Medicine, 2008, 15(1):34-41.
[9] 万文徽. 单克隆抗体亲和常数的测定. 单克隆抗体通讯, 1993,9(2):72-75. Wan W H. Measurement of monoclonal antibody affinity. Journal of Monoclonal Antibody,1993,9(2):72-75.
[10] Collins P L,Crowe J E.Respiratory syncytial virus and metapneumovirus.In:Knipe D M,Howley PM,Griffin D E,et a1.Fields Virology.5th ed.Philadelphia:Lippincott Williams ＆ Wilkins,2007.1601-1646.
[11] Bourgeois C, Corvaisier C, Bour J B, et al. Use of synthetic peptides to locate neutralizing antigenic domains on the fusion protein of respiratory syncytial virus. J Gen Virol, 1991,72(5):1051-1058.
[12] McLellan J S, Chen M, Chang J S, et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol, 2010, 84(23): 12236-12244.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
